Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Drug Discovery: Overview01:26

Drug Discovery: Overview

12.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.4K
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

81
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
81
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

65
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Genomics02:02

Genomics

41.1K
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
41.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Verifying models of the underwater soundscape from wind and ships with benchmark scenariosa).

The Journal of the Acoustical Society of America·2024
Same author

Detection range of a passing submerged emitter of sound in ambient noisea).

The Journal of the Acoustical Society of America·2024
Same author

Cross-disease spillover from research funding: Evidence from four diseases.

Social science & medicine (1982)·2024
Same author

The role of leadership in times of systems disruption: a qualitative study of health and social care integration.

BMJ open·2022
Same author

Implementing learning health systems in the UK NHS: Policy actions to improve collaboration and transparency and support innovation and better use of analytics.

Learning health systems·2020
Same author

Use of Real-World Data Sources for Canadian Drug Pricing and Reimbursement Decisions: Stakeholder Views and Lessons for Other Countries.

International journal of technology assessment in health care·2019

Related Experiment Video

Updated: Mar 1, 2026

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

2.2K

The Structural Genomics Consortium: A Knowledge Platform for Drug Discovery: A Summary.

Molly Morgan Jones, Sophie Castle-Clarke, Daniel Brooker

    Rand Health Quarterly
    |June 1, 2017
    PubMed
    Summary

    The Structural Genomics Consortium (SGC) uses an open-access model for drug discovery collaboration. An independent evaluation assessed its role, funding, and future opportunities in the R&D landscape.

    More Related Videos

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
    05:53

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

    Published on: June 21, 2018

    10.8K
    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
    05:10

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

    Published on: December 11, 2016

    10.3K

    Related Experiment Videos

    Last Updated: Mar 1, 2026

    A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
    07:35

    A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

    Published on: October 13, 2023

    2.2K
    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
    05:53

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

    Published on: June 21, 2018

    10.8K
    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
    05:10

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

    Published on: December 11, 2016

    10.3K

    Area of Science:

    • Biomedical Research
    • Drug Discovery
    • Open Science

    Background:

    • The Structural Genomics Consortium (SGC) operates on a public-private collaboration model.
    • The SGC facilitates drug discovery through open access principles.

    Purpose of the Study:

    • To independently evaluate the SGC's role and open access model in drug discovery.
    • To assess the SGC's strengths, weaknesses, opportunities, and threats.
    • To analyze funding incentives and future R&D trends impacting the SGC.

    Main Methods:

    • Independent evaluation by RAND Europe and the Institute on Governance.
    • Qualitative assessment of the SGC's model and external environment.
    • Quantitative analysis of the SGC's performance track record.
    • Scenario development for the SGC's future.

    Main Results:

    • The SGC's open access model was evaluated against alternative R&D funding strategies.
    • Incentives, disincentives, strengths, weaknesses, opportunities, and threats were identified.
    • The study provided insights into the SGC's past and current performance.
    • External environmental factors and actor roles in future scenarios were analyzed.

    Conclusions:

    • The evaluation informs current funding arguments and identifies trade-offs for the SGC's next phase.
    • It assesses funder expectations regarding the SGC and public-private partnerships (PPPs).
    • The study offers a framework for understanding the SGC's strategic positioning and future trajectory.